This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor.— The article by Dr O'Leary and colleagues¹ has important clinical implications. The results suggest that PAPNET-automated rescreening (Neuromedical Systems Inc, Suffern, NY) has little clinical utility since the cost does not justify the few incremental cases of cervical disease it may detect. This article confirms what many epidemiologists, clinicians, and scientists have suspected all along. Although the concept is sound, there is no automated rescreening technology to date that can address the poor sensitivity and specificity of the Papanicolaou (Pap) smear in cervical cancer screening.

The reported lack of sensitivity for the Pap smear ranges from 30% to 50% for significant disease (eg, high-grade dysplasias and cervical cancer) and as high as 50% for low-grade precursor lesions. Specificity is the primary concern for atypical squamous cells of undetermined significance (ASCUS) Pap smear results (25%).² In the majority of ASCUS cases, the cervix is normal; however, there are . . . [Full Text of this Article]